Myovant Sciences Ltd (MYOV) Fundamental Analysis & Valuation

NYSE:MYOV • BMG637AM1024

26.98 USD
-0.01 (-0.04%)
At close: Mar 9, 2023
26.98 USD
0 (0%)
After Hours: 3/9/2023, 8:04:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This MYOV fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

MYOV gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 520 industry peers in the Biotechnology industry. MYOV has a bad profitability rating. Also its financial health evaluation is rather negative. MYOV is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. MYOV Profitability Analysis

1.1 Basic Checks

  • MYOV had negative earnings in the past year.
  • MYOV had a negative operating cash flow in the past year.
MYOV Yearly Net Income VS EBIT VS OCF VS FCFMYOV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 0 200M -200M

1.2 Ratios

  • MYOV has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MYOV Yearly ROA, ROE, ROICMYOV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 0 -2K -4K -6K

1.3 Margins

  • With an excellent Gross Margin value of 73.03%, MYOV belongs to the best of the industry, outperforming 84.43% of the companies in the same industry.
  • MYOV does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 73.03%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MYOV Yearly Profit, Operating, Gross MarginsMYOV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 0 -100 -200 -300 -400

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. MYOV Health Analysis

2.1 Basic Checks

  • MYOV does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for MYOV has been increased compared to 1 year ago.
  • The debt/assets ratio for MYOV is higher compared to a year ago.
MYOV Yearly Shares OutstandingMYOV Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M
MYOV Yearly Total Debt VS Total AssetsMYOV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 200M 400M 600M

2.2 Solvency

  • Based on the Altman-Z score of -2.98, we must say that MYOV is in the distress zone and has some risk of bankruptcy.
  • MYOV's Altman-Z score of -2.98 is on the low side compared to the rest of the industry. MYOV is outperformed by 60.53% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -2.98
ROIC/WACCN/A
WACC7.64%
MYOV Yearly LT Debt VS Equity VS FCFMYOV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 200M -200M -400M

2.3 Liquidity

  • A Current Ratio of 1.57 indicates that MYOV should not have too much problems paying its short term obligations.
  • Looking at the Current ratio, with a value of 1.57, MYOV is doing worse than 84.43% of the companies in the same industry.
  • A Quick Ratio of 1.45 indicates that MYOV should not have too much problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 1.45, MYOV is doing worse than 83.96% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.57
Quick Ratio 1.45
MYOV Yearly Current Assets VS Current LiabilitesMYOV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. MYOV Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 22.67% over the past year.
  • Looking at the last year, MYOV shows a very strong growth in Revenue. The Revenue has grown by 91.46%.
EPS 1Y (TTM)22.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.24%
Revenue 1Y (TTM)91.46%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%84.11%

3.2 Future

  • The Earnings Per Share is expected to grow by 25.08% on average over the next years. This is a very strong growth
  • The Revenue is expected to grow by 45.18% on average over the next years. This is a very strong growth
EPS Next Y19.42%
EPS Next 2Y25.59%
EPS Next 3Y20.67%
EPS Next 5Y25.08%
Revenue Next Year81.1%
Revenue Next 2Y53.4%
Revenue Next 3Y43.72%
Revenue Next 5Y45.18%

3.3 Evolution

MYOV Yearly Revenue VS EstimatesMYOV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 500M 1B 1.5B
MYOV Yearly EPS VS EstimatesMYOV Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 2 -2 -4

More info and screens

Find the best growth stocksShow best growing peers

1

4. MYOV Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for MYOV. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MYOV. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MYOV Price Earnings VS Forward Price EarningsMYOV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MYOV Per share dataMYOV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4

4.3 Compensation for Growth

  • MYOV's earnings are expected to grow with 20.67% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.59%
EPS Next 3Y20.67%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. MYOV Dividend Analysis

5.1 Amount

  • MYOV does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

MYOV Fundamentals: All Metrics, Ratios and Statistics

Myovant Sciences Ltd

NYSE:MYOV (3/9/2023, 8:04:00 PM)

After market: 26.98 0 (0%)

26.98

-0.01 (-0.04%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)01-26
Earnings (Next)05-08
Inst Owners0%
Inst Owner Change0%
Ins Owners55.37%
Ins Owner Change0%
Market Cap2.62B
Revenue(TTM)379.11M
Net Income(TTM)-183.77M
Analysts76
Price Target27.54 (2.08%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-8.15%
Min EPS beat(2)-21.77%
Max EPS beat(2)5.48%
EPS beat(4)2
Avg EPS beat(4)1.97%
Min EPS beat(4)-21.77%
Max EPS beat(4)32.17%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)2.97%
Min Revenue beat(2)-4%
Max Revenue beat(2)9.95%
Revenue beat(4)2
Avg Revenue beat(4)4.58%
Min Revenue beat(4)-12.72%
Max Revenue beat(4)25.09%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)1.22%
EPS NY rev (3m)1.22%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)1.22%
Revenue NY rev (3m)1.22%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.92
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.91
EYN/A
EPS(NY)-0.93
Fwd EYN/A
FCF(TTM)-2.78
FCFYN/A
OCF(TTM)-2.78
OCFYN/A
SpS3.9
BVpS-5.74
TBVpS-5.74
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 73.03%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.94
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 65.14%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.57
Quick Ratio 1.45
Altman-Z -2.98
F-Score1
WACC7.64%
ROIC/WACCN/A
Cap/Depr(3y)67.93%
Cap/Depr(5y)160.76%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)22.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.24%
EPS Next Y19.42%
EPS Next 2Y25.59%
EPS Next 3Y20.67%
EPS Next 5Y25.08%
Revenue 1Y (TTM)91.46%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%84.11%
Revenue Next Year81.1%
Revenue Next 2Y53.4%
Revenue Next 3Y43.72%
Revenue Next 5Y45.18%
EBIT growth 1Y30.82%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year41.53%
EBIT Next 3Y15.08%
EBIT Next 5Y36.76%
FCF growth 1Y-161.11%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-160.74%
OCF growth 3YN/A
OCF growth 5YN/A

Myovant Sciences Ltd / MYOV FAQ

What is the fundamental rating for MYOV stock?

ChartMill assigns a fundamental rating of 2 / 10 to MYOV.


What is the valuation status for MYOV stock?

ChartMill assigns a valuation rating of 0 / 10 to Myovant Sciences Ltd (MYOV). This can be considered as Overvalued.


Can you provide the profitability details for Myovant Sciences Ltd?

Myovant Sciences Ltd (MYOV) has a profitability rating of 0 / 10.


Can you provide the financial health for MYOV stock?

The financial health rating of Myovant Sciences Ltd (MYOV) is 1 / 10.